ABSTRACT: An open mul ticentre study was conducted at 18 Canadian cen tres in patients diagnosed as suffering from irritable bowel syndrome ((BS). One hundred and thirty-one (72'!!, fe m ale and 28°1o male) patients, mean age 44 years, were treated w;:h 200 mg tid trimebuti ne maleatc (Modulon; Jouveinal) for periods of four weeks. Frequency and severi ty of pain, constipation and d iarrhea were a nalyzed, as were stool frequency a nd consistency. A statistically significant reduction of freq uency and severity was discerned in all symptoms (pain, constipation. diarrhea). Stool frequency foll within normal range (three per week to three per d ay) in close to 90% of patients as compared to 66% prior to the study. Si milarl y, stool consistency was normal in over 40°1o more patien ts at the end of the study than before treatment. G lobal evaluation by physicians a nd patients showed that approx imately 70% of patien ts felt better at the e nd of the treatment than before the study. Side effects such as nausea, headaches and fatig ue were reported in 14 patients.leading to discontinuation of therapy in seven. In conclusion , trimebuti ne maleate was effective in reduci ng the frequency and severity of the major sym ptoms of !BS as well as in normalizing transit distu rbances as measured by stool frequency. Can J Gastrocnterol 1987; 1(1):23-27
T HE GREAT MAJORITY OF PATIENTS
with irritable bowel syndrome (JBS) present with a multi tude of symptoms, all of which arc often not responsive to a single agent such as a n cicholinergics or antispasmodics wh ich a rc prescribed fo r pain , antidiarrheal agents. d ietary fibre for transirdisturbanccs and antidepressants/ anxio lytics for patients with associated psychological problems. Rather, a combination of several agents must often be prescribed. Thus. agents capable of contro ll ing the entire sy mptom com pl ex under monothcrapy would offer an obvious advantage.
Trimcbutinc maleatc (malemc sal t of 2-dimethyl-ami no-2-phenylbu tyl 1.4. 5 trimethoxy benzoatc) was shown to stimulate motility in the small intestine and to modulare it in the colon , and to possess nonspecific sp asmo lyric acti vity associa ted with local anesthe tic p roperties. Its stimulant activity appears to be related mostly to peripheral µ e nkephalin e rgic agonist activity, while the in hibitory effect is mediated by irs interaction with K receptors ( I). In preclinical studies. it was shown to exert regularizing effect on abnormal con tractiliry in vitro, as well as in vivo, where it induced phase Ill activity in dog intestine (2). In human intestine, it induces phase lll activity (3), accelerates duodenal transit ( 4) and stim-ulate:, spikt, potential activity ( ' 1 ). These effects have bct.>n fou nd useful in accelerating the resolution of rostoperative paralytic ileus ( 5,6 L ln the colon, the drug seems to exhibit bivalent action, as was demonstrated in sLUdies where it reduced abnormnlly elevated and stimulated abnormally diminished colonic motor and clcctromyogenic nctivities ( 7-9). It appears to exert no effect on normal colonic activity ( 3.7.8). Frexinos ( 10) showed that the drug is active in both constipated and dinrrheic pnricms in char ir reduces colonic long spike burst clectromyogcnic activity. All these parameters -;eem to be related co the drug's ability Lo reduce clinical sym ptoms of !BS. Numerous controlled cl intrnl triab evalunring the effect of trimebutine maleate in the treatment of !BS have been completed (12) (13) (14) . Short m medium term studies ( three days to four weeks) comparing the drug to placebo showed that it is significantly more effective than placebo. rarticularly in relieving pain and constipation. Unpublished reports indicate that it also reduces diarrhea. Single ·mol transit time was significantly reduced in constipated patients with spastic colon ( I 3). In a six month study, no sign ificant differences in global assessment were found between the drug and placebo in patients treated concomnancly with high fibre diet. although colon tenderness was signific,mtly reduced at three months ( 15) . Studies comparing tnmd1-utine 10 meheverinl' ( 16, 17) . antichnlincrgics such as pi navenum bromide ( 1/{) and cl idm 1um hrom1de/chlordtazepoxide combinntion ( 19) . showed equivalent efficacy in ;ill treatment groups.
A post marketing open multiccntre study was conducted in order co C1hsl.'rve the effect of rrimebu tine maleate 111 the treatment of !BS and its variC1us su bgroups within rhe scope nf routine gasrroenterology practice
MATERIALS AND METHODS
Eighteen Canadinn centres participated in the study. Patient selection criteria included presence of chronic abdominal pain and/or transit disrurhances such ;is constip:ition. di:irrhca and alternation of the two. P;irien ts must h;wl' h:id no evidence of organic gastrotntestinal disease as demonstrated by barium 24 enema. sigmoidoscopy. hemograrn, blood biochemistry and/or lacmsc colerance test. Only patients symptomatic m che time of entry into the study were to be included.
Patients were treated with two 100 mg trimcbutine maleacc tablets three times a day ( 30 mins before meals) during four weeks, with follow-up every two weeks. Other medications for lBS were continued throughout the study with the exceptinn of anticholinergics wh ich were discontinued in ;ill but rwo p;itients, starting at least 48 h prior ro entry into the study Although these two patients would have been excluded in a double-blind study analysis. they were included in th is case.
During the trial. patients completed daily diary cards su mmarizing their intest1nal habits and intensity of symptoms. Study sample: Twenty-one invcsci gators entered 146 patients at 18 centres throughout Canad;1 Fifteen patients fai led to return after their initi:11 rnnsultation and were excl uded from the study.
Another 11 discontinUL'd du e to lack of improvement (four) or side effects (seven). The initial demographic data arr summa rized in Table I The usual spec· trum of the syndrome was well rcprc· scnted in the study sample RESULTS Symptom severity: A statisucallv sign ificant reduction of severity wa, ob served in all sympwms ( pain, constipation, di:mhea) (Tc1hlc 2, l=igure I).
At the wm ot the st ud y, 91 "i, of pa· Inc ide n ce of pa in : In the pain subgroup. incidence of pain was significantly reduced fro m a mean of 5 2 to 2. 7 days per week and the percenrnge of p::nients reporting pain decreased from 99 ro 62''., (Table 1) . B o we l h ab it: The numher of p;lltents wtth stool frequency w1thin the normal range ( th rec per day to three pt'r Wl'ek) increased signtficantly from 64 to 85"o following treatment (Table 4 . Figure , ) .
Stool consistency became significantly (P -.. 0.000 I) more frequently normal in the entire study sample. Abnorma l stool consistency ( watery or hard) was reported 76'\, of the time p rior ro and H"li following treatment. G loba l evaluatio n : Overall condttion was assessed as better than before treatment in about 70"., of the patients.
Only six panenrs considered thetr wnditicm worse (Ta hie 5). Symr,tom improvcmentobrnmed with trimeb utinc maleate occurred within tht first two weeks of treatment and w::is sus· rained or con tinued u p to the end of the study. Patients continuing treatment beyond the durnuon of the studv repon con tin ued long term benefit. It appear~ th::it, in certain patients, the efficacy ot the drug increases with continued treat men t. The drug was generally well tolcr· ared and offers a viable all round thcra pcutic alternative in the treatment of ms. Dcbridat (mmchutine) , ur la motrirn(·
